Emerging Approaches in Schizophrenia

More News and Clinical Research about Emerging Approaches in Schizophrenia

Commentary

Xanomeline-Trospium Tolerability: Commentary

February 26, 2025

The author discusses new findings from Kaul et al on the safety and tolerability of xanomeline-trospium.

Leslie Citrome

Safety and Tolerability of Xanomeline and Trospium Chloride in Schizophrenia: Pooled Results From the EMERGENT Trials

Original Research

Safety and Tolerability of Xanomeline and Trospium Chloride in Schizophrenia: Pooled Results From the EMERGENT Trials

February 26, 2025

In pooled analyses, xanomeline/trospium was generally well tolerated. The most common adverse events were mild or moderate, transient, and consistent with the activity of xanomeline and trospium at muscarinic…

Inder Kaul, Amy Claxton, Sharon Sawchak, et al

Study Unveils Link Between Manic Symptoms and Schizophrenia

news

Study Unveils Link Between Manic Symptoms and Schizophrenia

February 19, 2025

New research shows that the severity of positive symptoms in schizophrenia spectrum disorders predicts the presence of manic symptoms.

Lifting the Veil on Schizophrenia and Substance Use Disorders

news

Lifting the Veil on Schizophrenia and Substance Use Disorders

February 12, 2025

Research highlights a strong link between substance use disorders and schizophrenia, while treatment challenges persist.

Researchers Propose a Periodic Table of Psychiatric Disorders

news

Researchers Propose a Periodic Table of Psychiatric Disorders

February 5, 2025

Stanford researchers propose a “periodic table” of brain cell types to map psychiatric disorders and drive tailored treatments.

Study Finds Best Way to Prevent Schizophrenia Relapse

news

Study Finds Best Way to Prevent Schizophrenia Relapse

January 29, 2025

A Finnish study suggests earlier use of clozapine after a first relapse in schizophrenia significantly reduces relapse risks.

The Road Between The Gut And Schizophrenia Runs Both Ways

news

The Road Between The Gut And Schizophrenia Runs Both Ways

January 22, 2025

New research reveals a strong link between the gut microbiome and schizophrenia, highlighting the potential for gut-targeted therapies.

Sulforaphane Added to Antipsychotics for Negative Symptoms of Schizophrenia

Original Research

Sulforaphane Added to Antipsychotics for Negative Symptoms of Schizophrenia

January 20, 2025

Add-on high dose sulforaphane may reduce negative symptoms in patients with schizophrenia, although the clinical significance of this reduction needs further evaluation.

Jing Huang, AnMei Chen, Hua Jin, et al

Gut Microbiome Breakthroughs Revolutionize Schizophrenia Treatment

news

Gut Microbiome Breakthroughs Revolutionize Schizophrenia Treatment

January 15, 2025

A growing body of research has revealed a link between the gut microbiome and mental disorders, such as treatment-resistant schizophrenia.

Olanzapine/Samidorphan Effects on Weight Gain

Original Research

Olanzapine/Samidorphan Effects on Weight Gain

January 2, 2025

Treatment with a combination of olanzapine and samidorphan was associated with less weight gain and reduced risk of reaching ≥7% or ≥10% gain in body weight versus olanzapine over…

Christoph U. Correll, Michael J. Doane, David McDonnell, et al

Unified Brain Network Links Schizophrenia Atrophy

news

Unified Brain Network Links Schizophrenia Atrophy

December 12, 2024

Researchers identified a brain network tied to schizophrenia, allowing for earlier detection and targeted treatments.

Could Intermittent Theta Burst Stimulation Treat Schizophrenia?

news

Could Intermittent Theta Burst Stimulation Treat Schizophrenia?

December 3, 2024

Intermittent theta burst stimulation (iTBS) over the left dorsolateral prefrontal cortex shows promise as a schizophrenia treatment.

« 1 2 3 4 5 »